Drug
Rc118 Plus Rc148
Rc118 Plus Rc148: highest development phase Phase 2/3, developed by RemeGen Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- RemeGen Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| RC118(Dose 1) plus RC148(Dose 1) NCT07935369 | Phase 2/3 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
Latest
No recent events.
Follow Rc118 Plus Rc148 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.